Inspire Advisors LLC Purchases 233 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Inspire Advisors LLC increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 11.8% in the first quarter, Holdings Channel reports. The institutional investor owned 2,200 shares of the medical research company’s stock after acquiring an additional 233 shares during the period. Inspire Advisors LLC’s holdings in IQVIA were worth $556,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of IQV. Norges Bank bought a new stake in IQVIA in the fourth quarter worth $383,705,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in IQVIA by 339.6% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after buying an additional 1,597,003 shares during the last quarter. Morningstar Investment Services LLC lifted its position in shares of IQVIA by 96.9% during the fourth quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock worth $286,704,000 after purchasing an additional 606,333 shares during the last quarter. Capital Research Global Investors lifted its position in shares of IQVIA by 42.2% during the fourth quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock worth $461,675,000 after purchasing an additional 592,372 shares during the last quarter. Finally, Cadian Capital Management LP bought a new stake in shares of IQVIA during the fourth quarter worth $70,108,000. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Truist Financial decreased their target price on IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a research report on Friday, May 3rd. Robert W. Baird decreased their target price on IQVIA from $241.00 to $235.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Barclays decreased their target price on IQVIA from $275.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, June 28th. Evercore ISI decreased their price objective on IQVIA from $250.00 to $230.00 and set an “outperform” rating for the company in a report on Tuesday, July 9th. Finally, The Goldman Sachs Group initiated coverage on IQVIA in a report on Thursday, June 6th. They issued a “buy” rating and a $270.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $255.73.

IQVIA Stock Up 2.2 %

IQV traded up $5.07 on Tuesday, hitting $230.96. The company had a trading volume of 270,984 shares, compared to its average volume of 1,059,893. The stock has a fifty day moving average price of $219.69 and a 200-day moving average price of $228.91. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.88 and a current ratio of 0.88. The stock has a market capitalization of $42.08 billion, a price-to-earnings ratio of 30.86, a P/E/G ratio of 2.04 and a beta of 1.49.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Analysts predict that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.